Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
| Image |  |
|---|---|
| Description | scientific article published on 26 November 2019 |
| Author/s |
author: Mark Geyer |
| Publication date | November 26, 2019 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |